INOSINE PRANOBEX

Details

Stereochemistry	MIXED
Molecular Formula	C10H12N4O5.3C9H9NO3.3C5H13NO
Molecular Weight	1115.2325
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 7
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC2=CC=C(C=C2)C(O)=O.CC(=O)NC3=CC=C(C=C3)C(O)=O.OC[C@H]4O[C@H]([C@H](O)[C@@H]4O)N5C=NC6=C5N=CNC6=O

InChI

InChIKey=YLDCUKJMEKGGFI-QCSRICIXSA-N

InChI=1S/C10H12N4O5.3C9H9NO3.3C5H13NO/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18;3*1-6(11)10-8-4-2-7(3-5-8)9(12)13;3*1-5(7)4-6(2)3/h2-4,6-7,10,15-17H,1H2,(H,11,12,18);3*2-5H,1H3,(H,10,11)(H,12,13);3*5,7H,4H2,1-3H3/t4-,6-,7-,10-;;;;;;/m1....../s1

HIDE SMILES / InChI

Molecular Formula	C10H12N4O5
Molecular Weight	268.2261
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C9H9NO3
Molecular Weight	179.1727
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C5H13NO
Molecular Weight	103.1628
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.medicines.org.uk/emc/medicine/27089
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/2431857

Inosine pranobex is an antiviral drug that is a combination of inosine and dimepranol acedoben (a salt of acetamidobenzoic acid and dimethylaminoisopropanol) in a ratio of 1 to 3. Inosine pranobex is used to treat mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. The in vivo antiviral and activity of inosine pranobex is believed to result from an enhancement of host immune responses due to the drug. The drug does not by itself stimulate resting lymphocytes, but augments immunological processes by lymphocytes once they have been triggered by mitogens or viral antigens.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
immune response 6 Target ID: GO:0006955 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2431857	Modulator 828

Conditions

Condition	Modality	Highest Phase	Product
Herpes simplex infection 28 Sources: https://www.medicines.org.uk/emc/medicine/27089	Primary	Approved 8429	IMUNOVIR Approved Use Imunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date 1983
Genital warts 14 Sources: https://www.medicines.org.uk/emc/medicine/27089	Primary	Approved 8429	IMUNOVIR Approved Use Imunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date 1983
Subacute sclerosing panencephalitis 4 Sources: https://www.medicines.org.uk/emc/medicine/27089	Primary	Approved 8429	IMUNOVIR Approved Use Imunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date 1983

PubMed

Title	Date	PubMed
Effect of isoprinosine against influenza and some other viruses causing respiratory diseases.	1972 Sep	4790561
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.	1992 Sep	1416885
Effect of isoprinosine on rotavirus replication in vitro.	1996 Feb	8731352

Patents

Sample Use Guides

In Vivo Use Guide

Mucocutaneous herpes simplex: 1 g q.d.s. (4g daily), for 7 -14 days. Genital warts: 1g t.d.s. (3g daily), for 14-28 days as adjunctive therapy to podophyllin or carbon dioxide laser. Subacute sclerosing panencephalitis (SSPE): 50-100mg/kg daily, in divided does every 4 hours.

Route of Administration: Oral

In Vitro Use Guide

Inosine pranobex has been shown to stimulate various indices of metabolic activity of macrophages and monocytes. In vitro exposure to inosine pranobex or to 24-hour supernatants obtained from mononuclear cells pretreated with the drug restored chemotaxis to normal or near normal levels. Incubation with inosine pranobex in vitro stimulated the production of interleukin-l (lymphocyte activating factor) in human monocytes.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:22:31 GMT 2023` Edited by `admin` on `Fri Dec 15 15:22:31 GMT 2023`
Record UNII	W1SO0V223F
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

INOSINE PRANOBEX

Common Name

English

INOSINE PRANOBEX [JAN]

Common Name

English

IMUNOVIR

Brand Name

English

INOSINE ACEDOBENE DIMEPRANOL

Common Name

English

AVIRAL

Brand Name

English

IAD

Common Name

English

INOSINE-2-HYDROXYPROPYLDIMETHYLAMMONIUM 4-ACETAMIDOBENZOATE (1:3)

Common Name

English

INOSIPLEX

Common Name

English

ISOPRINOSINA

Brand Name

English

PRANOSINA

Brand Name

English

NP-113

Code

English

Inosine pranobex [WHO-DD]

Common Name

English

METHISOPRINOL

Common Name

English

ISOPRINOSINE

Brand Name

English

MODIMMUNAL

Brand Name

English

INOSINE PRANOBEX [MI]

Common Name

English

ISOVIRAL

Brand Name

English

INOSINE PRANOBEX [MART.]

Common Name

English

IMUNOVIRAL

Brand Name

English

DELIMMUN

Brand Name

English

VIRUXAN

Brand Name

English

ISOPRINOSIN

Brand Name

English

PRANOSINE

Brand Name

English

NPT-10381

Code

English

Classification Tree Code System Code

WHO-VATC

QJ05AX05